Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Novo Files Oral Semaglutide in Japan
July 25, 2019
- Ayumi to Ease Restrictions on Enbrel Biosimilar Use as Product Boost Progresses
July 24, 2019
- HIF-PH Inhibitor Vadadustat Submitted in Japan: Mitsubishi Tanabe
July 24, 2019
- Lenvima/Keytruda Gets FDA’s Breakthrough Status for HCC
July 24, 2019
- Dissolving JV with Takeda, PRA Launches Independent CRO Biz in Japan
July 24, 2019
- Boehringer Said to Consider Nixing Allowances for Some Wholesalers, Denies Intention to Narrow Distributors
July 23, 2019
- Lonasen Effective in Adolescent Japanese Schizophrenia Patients: Sumitomo Dainippon
July 23, 2019
- Nichi-Iko Gets Distribution Rights to Chugai’s Ulcerlmin
July 23, 2019
- Shire’s Vonvendi Filed in Japan
July 23, 2019
- Aspen Japan to Take Over Bristol’s Antiarrhythmic Agent
July 23, 2019
- Ono/BMS, Bayer to Develop Opdivo-Stivarga Combo
July 22, 2019
- Sumitomo Dainippon Offers to Buy Cynata
July 22, 2019
- Nitto Pharma Accelerating Development of Gut Bacteria Drugs, Eyes Clinical Studies within 3 Years
July 22, 2019
- Tarlige Most Pitched Drug in April: Impact Track Survey
July 19, 2019
- BACE Inhibitor Elenbecestat Shows No Major Effect on Synaptic Function in Nonclinical Study: Eisai
July 19, 2019
- IPO Pending, StemRIM Looks to File World’s 1st Regeneration-Inducing Med Next Year: CEO
July 18, 2019
- Astellas Hitches Frequency’s Regenerative Hearing Loss Therapy Outside US
July 18, 2019
- Astellas/Seattle Genetics’ ADC Filed in US for Urothelial Cancer
July 18, 2019
- Halaven Bags China Approval for Breast Cancer: Eisai
July 18, 2019
- Ono’s Yamaguchi Plant Completed, Set to Go Live Next Spring
July 18, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…